美沙拉秦(Salofalk)的用药指南

Mesalazine (Salofalk) needs to follow a strict dosage regimen and individualized management for special groups, and strictly follow the doctor's instructions.

Mesalazine (Salofalk) usage and dosage

1. Adults and the elderly

Unless otherwise directed by a doctor, the recommended dosage is as follows (taken in 1-3 times a day):

(1) Acute phase treatment:

Ulcerative colitis: 1.5-3g daily.

Crohn’s ileitis and colitis: 3–4.5g daily.

(2), maintenance of remission and long-term treatment:

Ulcerative colitis: 1.5g daily.

Crohn’s ileitis and colitis: 1.5–3g daily.

2. Children over 6 years old (only applicable to ulcerative colitis)

(1), acute phase treatment: 30-50mg/kg body weight daily;

(2), remission phase maintenance: 15-30mg/kg body weight daily.

For those weighing ≤40kg, half the adult dose can be used, and for those >40kg, the full adult dose can be taken. The total daily dose should not exceed the maximum adult dose.

3. How to take the medicine

Swallow the tablet whole, do not chew or crush it, and take it with enough liquid. It is recommended to take it at least 1 hour before a meal to facilitate gastric emptying.

4. Treatment course recommendations

During the acute attack period, medication needs to be taken regularly to achieve the desired effect. Usually, an acute attack of ulcerative colitis or Crohn's disease can be relieved within 8 weeks.

The pictures are from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Mesalazine (Salofalk) Medication for Special Populations

1. Pregnant women

Human data are limited and should be used only when clearly needed after weighing the pros and cons.

2. Breastfeeding women

Drugs can enter breast milk and may cause diarrhea in infants. Its use is not recommended unless the benefits of treatment clearly outweigh the risks.

3. Liver function impairment

Patients with mild to moderate impairment should use it with caution and closely monitor liver function. Those with severe liver impairment are prohibited from using it.

4. Renal function impairment

It is not recommended for patients with renal insufficiency. If it must be used, renal function (such as serum creatinine, urea nitrogen) must be closely monitored before and during treatment. If deterioration occurs, the drug should be discontinued immediately.

5. Elderly people

Clinical data are limited, but it is available for patients under 75 years old, and renal function needs to be monitored.

6. Children

Children under 6 years old are not suitable for ulcerative colitis, and children under 12 years old are not suitable for Crohn's disease, because the experience with medication in this age group is very limited.

7. Men and women of reproductive potential

Animal studies have not shown an effect on fertility, and human data are insufficient.

Pharmacokinetics of mesalazine (Salofalk)

1. Absorption

Mesalazine has a low absorption rate in the distal intestine and is mainly excreted in the feces.

2. Distribution

The plasma protein binding rates are 43% for mesalazine and 78% for N-acetyl-5-ASA.

3. Metabolism

It is mainly acetylated into the inactive metabolite N-acetyl-5-ASA in the intestinal mucosa and liver.

4. Excretion

The kidneys excrete less than 1% of the original drug and about 24% of metabolites, and bile excretion is less.